Establishment Labs (NASDAQ:ESTA) Given Buy Rating at TD Cowen

Establishment Labs (NASDAQ:ESTA)‘s stock had its “buy” rating restated by equities research analysts at TD Cowen in a report issued on Thursday, Marketbeat reports. They currently have a $117.00 price target on the stock. TD Cowen’s price objective indicates a potential upside of 100.82% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ESTA. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, September 21st. Mizuho boosted their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Needham & Company LLC boosted their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.56.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $58.26 on Thursday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -44.47 and a beta of 1.06. Establishment Labs has a 12 month low of $47.00 and a 12 month high of $97.59. The firm’s 50-day moving average is $68.96 and its 200 day moving average is $74.51. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The business had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter in the previous year, the firm earned ($0.57) EPS. Establishment Labs’s revenue was up 31.7% compared to the same quarter last year. Research analysts predict that Establishment Labs will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds have recently modified their holdings of ESTA. BlackRock Inc. purchased a new stake in shares of Establishment Labs during the 2nd quarter worth $135,752,000. William Blair Investment Management LLC purchased a new stake in Establishment Labs during the second quarter valued at approximately $61,273,000. Bank of America Corp DE purchased a new stake in Establishment Labs during the second quarter valued at approximately $52,176,000. Rice Hall James & Associates LLC purchased a new stake in Establishment Labs during the second quarter valued at approximately $48,134,000. Finally, Nantahala Capital Management LLC purchased a new stake in Establishment Labs during the second quarter valued at approximately $28,817,572. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc (NASDAQ: ESTA) is a medical technology company focused on women’s health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets.